Cargando…

A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas

OBJECTIVE: Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). METHODS: Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bowen, Wang, Jiu, Liu, Fangfang, Li, Rui, Hu, Weihong, Etcheverry, Amandine, Aubry, Marc, Mosser, Jean, Yin, Anan, Zhang, Xiang, Wu, Yuanming, Chen, Kun, He, Yalong, Wang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194959/
https://www.ncbi.nlm.nih.gov/pubmed/35712126
http://dx.doi.org/10.1155/2022/6345160
_version_ 1784726859810865152
author Li, Bowen
Wang, Jiu
Liu, Fangfang
Li, Rui
Hu, Weihong
Etcheverry, Amandine
Aubry, Marc
Mosser, Jean
Yin, Anan
Zhang, Xiang
Wu, Yuanming
Chen, Kun
He, Yalong
Wang, Li
author_facet Li, Bowen
Wang, Jiu
Liu, Fangfang
Li, Rui
Hu, Weihong
Etcheverry, Amandine
Aubry, Marc
Mosser, Jean
Yin, Anan
Zhang, Xiang
Wu, Yuanming
Chen, Kun
He, Yalong
Wang, Li
author_sort Li, Bowen
collection PubMed
description OBJECTIVE: Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). METHODS: Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined from the methylation state of pseudogene loci. Both bioinformatic and experimental analyses were performed for biological validation. RESULTS: By integrating clinical information with DNA methylation microarray data, we screened a panel of eight CpGs from discovery cohorts of non-G-CIMP GBMs. Each CpG could accurately and independently predict the prognosis of patients under a treatment regime that combined radiotherapy (RT) and temozolomide (TMZ). The 8-CpG signature appeared to show opposite prognostic correlations between patients treated with RT/TMZ and those treated with RT monotherapy. The analyses further indicated that this signature had predictive value for TMZ efficacy because different survival benefits between RT/TMZ and RT therapies were observed in each risk subgroup. The incorporation of other risk factors, such as age and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, with our pseudogene methylation signature could provide precise risk classification. In vitro experimental data revealed that two locus-specific pseudogenes (ZNF767P and CLEC4GP1) may modulate TMZ resistance via distinct mechanisms in GBM cells. CONCLUSION: The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches.
format Online
Article
Text
id pubmed-9194959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-91949592022-06-15 A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas Li, Bowen Wang, Jiu Liu, Fangfang Li, Rui Hu, Weihong Etcheverry, Amandine Aubry, Marc Mosser, Jean Yin, Anan Zhang, Xiang Wu, Yuanming Chen, Kun He, Yalong Wang, Li J Oncol Research Article OBJECTIVE: Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). METHODS: Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined from the methylation state of pseudogene loci. Both bioinformatic and experimental analyses were performed for biological validation. RESULTS: By integrating clinical information with DNA methylation microarray data, we screened a panel of eight CpGs from discovery cohorts of non-G-CIMP GBMs. Each CpG could accurately and independently predict the prognosis of patients under a treatment regime that combined radiotherapy (RT) and temozolomide (TMZ). The 8-CpG signature appeared to show opposite prognostic correlations between patients treated with RT/TMZ and those treated with RT monotherapy. The analyses further indicated that this signature had predictive value for TMZ efficacy because different survival benefits between RT/TMZ and RT therapies were observed in each risk subgroup. The incorporation of other risk factors, such as age and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, with our pseudogene methylation signature could provide precise risk classification. In vitro experimental data revealed that two locus-specific pseudogenes (ZNF767P and CLEC4GP1) may modulate TMZ resistance via distinct mechanisms in GBM cells. CONCLUSION: The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches. Hindawi 2022-06-06 /pmc/articles/PMC9194959/ /pubmed/35712126 http://dx.doi.org/10.1155/2022/6345160 Text en Copyright © 2022 Bowen Li et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Li, Bowen
Wang, Jiu
Liu, Fangfang
Li, Rui
Hu, Weihong
Etcheverry, Amandine
Aubry, Marc
Mosser, Jean
Yin, Anan
Zhang, Xiang
Wu, Yuanming
Chen, Kun
He, Yalong
Wang, Li
A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
title A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
title_full A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
title_fullStr A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
title_full_unstemmed A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
title_short A Novel Pseudogene Methylation Signature to Predict Temozolomide Outcome in Non-G-CIMP Glioblastomas
title_sort novel pseudogene methylation signature to predict temozolomide outcome in non-g-cimp glioblastomas
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9194959/
https://www.ncbi.nlm.nih.gov/pubmed/35712126
http://dx.doi.org/10.1155/2022/6345160
work_keys_str_mv AT libowen anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT wangjiu anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT liufangfang anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT lirui anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT huweihong anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT etcheverryamandine anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT aubrymarc anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT mosserjean anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT yinanan anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT zhangxiang anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT wuyuanming anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT chenkun anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT heyalong anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT wangli anovelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT libowen novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT wangjiu novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT liufangfang novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT lirui novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT huweihong novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT etcheverryamandine novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT aubrymarc novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT mosserjean novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT yinanan novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT zhangxiang novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT wuyuanming novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT chenkun novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT heyalong novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas
AT wangli novelpseudogenemethylationsignaturetopredicttemozolomideoutcomeinnongcimpglioblastomas